United Therapeutics (NASDAQ:UTHR) Director Sells $510,000.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the transaction, the director directly owned 4,190 shares in the company, valued at $2,136,900. This trade represents a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher Causey also recently made the following trade(s):

• On Friday, January 2nd, Christopher Causey sold 1,000 shares of United Therapeutics stock. The stock was sold at an average price of $500.01, for a total value of $500,010.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $490.83 on Friday. The business’s 50-day simple moving average is $483.18 and its 200 day simple moving average is $400.13. The company has a market cap of $21.14 billion, a P/E ratio of 18.60, a PEG ratio of 2.61 and a beta of 0.84. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.39 EPS. Analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Chung Wu Investment Group LLC bought a new stake in United Therapeutics during the second quarter valued at $29,000. Abich Financial Wealth Management LLC acquired a new stake in shares of United Therapeutics during the third quarter worth $44,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on UTHR shares. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a report on Wednesday, October 29th. Wells Fargo & Company boosted their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. UBS Group upped their target price on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.